AbbVie Inc. s in-depth stock price analysis indicates that the stock price has dropped -0.17% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -6.49% . Looking at the past 52 week period, the stock price is up at 14.91% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of AbbVie Inc. has a positive value of 9.63 compared to overall market. AbbVie Inc. (NYSE:ABBV) has tumbled 0.41% during the past week and has dropped 2.53% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.22%. AbbVie Inc. (NYSE:ABBV) has underperformed the index by 4.28% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
AbbVie Inc. (NYSE:ABBV) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.42 points or 0.69% at $60.42 with 5,749,160 shares getting traded. Post opening the session at $60.85, the shares hit an intraday low of $60.27 and an intraday high of $61 and the price was in this range throughout the day. The company has a market cap of $98,188 million and the number of outstanding shares has been calculated to be 1,625,099,000 shares. The 52-week high of AbbVie Inc. (NYSE:ABBV) is $68.1239 and the 52-week low is $51.6.
AbbVie Inc Last issued its quarterly earnings results on Jan 27, 2017. The company reported $1.20 EPS for the quarter. Analyst had a consensus estimate of $1.20. The company had revenue of $6784.00 million for the quarter, compared to analysts expectations of $6902.70 million. The companys revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.13 EPS.
Company has reported several Insider transactions to the SEC, on Dec 2, 2016, William J Chase (EVP, Chief Financial Officer) sold 6,600 shares at 59.19 per share price.On Nov 18, 2016, Thomas A. Hurwich (VP, Controller) sold 3,100 shares at 62.00 per share price.On Sep 9, 2016, Laura J Schumacher (Executive Vice President) sold 50,000 shares at 65.00 per share price.
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The companys mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the worlds most complex and serious diseases. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions.